We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Laser Ablation in Liver Tumors

By HospiMedica staff writers
Posted on 21 Dec 2005
A 12-year study has found that laser ablation with magnetic resonance (MR) guidance is as effective as traditional surgery in the treatment of liver tumors in some patients.

In the largest study of its type and with the longest follow-up, 839 patients at the University of Frankfurt (Frankfurt, Germany) received MR-guided laser-induced thermotherapy (LITT), also known as laser ablation, to destroy tumor tissue. More...
The average survival rate from the date of diagnosis was 3.8 years, which compares favorably to survival rates after traditional surgery (approximately 1.5-5.0 years).

Laser ablation can be used to treat tumors that occur in both halves of the liver--often during the same treatment--which is practically impossible in traditional surgery where typically only the left or right lobe is resected. If new tumors are found during follow-up exams, it is much easier to repeat laser treatment than to subject the patient to another open surgery.

Laser treatment can be done on an outpatient basis under local anesthesia. Typically, the patient stays only several hours, instead of several weeks in the hospital after surgical liver resection

"Many surgeons are already performing local ablation instead of resection, because they have already recognized the positive effect of local ablation,” said the study's lead author, Dr. Martin Mack, an associate professor in the department of diagnostic and interventional radiology at the University of Frankfurt. "I believe that minimally invasive tumor ablation together with chemotherapy will play the most important role in the treatment of tumors in the years to come.”




Related Links:
University of Frankfurt

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.